Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ARCHIVE
ARCHIVE
- R-Tech Ueno Terminates Licensing Agreement for Human Serum Albumin with MTPC
August 30, 2010
- Fuji Pharma: Generic Diagnostics Drive Business
August 30, 2010
- Immunotherapy for Renal Cell Carcinoma Approved as Advanced Therapy
August 30, 2010
- R-Tech Ueno Applies for Arbitration in Disputes with Takeda over Agreement on Amitiza
August 30, 2010
- Eli Lilly Discontinues Development of Semagacestat for AD
August 30, 2010
- Cervarix Adverse Events Reported from 37 Recipients
August 30, 2010
- Alfresa to Make Tampei Nakata Wholly-Owned Subsidiary
August 30, 2010
- IPSN, INCJ to Invest in IP Rights in 4 Fields
August 30, 2010
- JCQHC Calls For a Rest for MTX
August 30, 2010
- Shionogi: Crestor Pulls Up Sales 17.5%
August 16, 2010
- Medipal HD: Sales up 4.7% with Strong Increases in Profits
August 16, 2010
- 5 APIs, 7 Indications to Be Applied for Based on Data from Public Domain
August 16, 2010
- Taisho: Self-Medication Makes Up for Slump of Ethical Drugs
August 16, 2010
- Alfresa: Profits Up as a Result of Firm Pricing Policy
August 16, 2010
- Korosho Posts Its Policy for Assessment of Research Projects
August 16, 2010
- Ono: Sales Down 7.2% due to NHI Price Cuts, Competition with Generics
August 16, 2010
- Suzuken: Sales Up 1.7% Based on New Sales Reporting Method
August 16, 2010
- JAMS Proposes GLs for COI to Member Societies
August 16, 2010
- Santen: Tapros Drives Business
August 16, 2010
- Toho: Addition of Saywell, Asucome Boosts Sales
August 16, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…